Autopsy report · NCT05381935

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

“Sponsor's clinical development strategy adjustment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Elpiscience Biopharma, Ltd.

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

ES014; ES014

Participants

0

Trials that died the same way

• A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
  “The sponsor adjusts the clinical development strategy.” (95% match in meaning)
• A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
  “Sponsor decision:Change the Development plan” (73% match in meaning)
• A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
  “Sponsor Decision; strategic - based on changing treatment landscape” (72% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (71% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.